TLDR
- PFE trades at a 9.43x non-GAAP P/E for 2026, well below the S&P 500’s 21.2x forward multiple
- 2026 revenue guidance of $60.5–$62.5 billion sits roughly 39% below its 2022 peak of $100.3 billion
- Pfizer raised R&D spending by about 13% in H1 2026 despite expecting a 2% revenue decline
- Cost-cutting programs target $9.7 billion in total net savings through 2029
- Wall Street gives PFE a Moderate Buy with an average price target of $28.46
Pfizer stock currently trades around $28.07, reflecting a 9.43x non-GAAP P/E multiple on 2026 expected earnings of $2.98 per share. That is a steep discount to the broader market’s 21.2x forward multiple.
The stock has returned 16.1% over the past year, putting it modestly ahead of the S&P 500 in 2026. But zoom out five years and the picture changes. PFE is still down 21.5% over that stretch, meaning longer-term holders are still waiting to get back to even.
The revenue story is not pretty right now. Pfizer’s updated 2026 guidance of $60.5–$62.5 billion is roughly 39% below its 2022 peak of $100.3 billion, when COVID vaccine and treatment sales were booming.
Post-pandemic demand for COVID products has fallen sharply. Patent expirations on drugs like Xeljanz are adding further pressure, with analysts projecting EPS to dip slightly from $2.98 in 2026 to $2.90 in 2027 as more exclusivity periods end.
Despite all of that, Pfizer is spending more, not less, on research. R&D spending rose about 13% in H1 2026, even as the company braces for a roughly 2% revenue decline this year.
The bet is on a pipeline payoff. Pfizer is targeting high single-digit compound revenue growth after 2028, driven by oncology, mRNA platforms, and cancer antibody-drug conjugate therapies. The Lyme disease vaccine candidate has also drawn attention.
Cost Cuts Add to the Equation
Manufacturing optimization and cost realignment programs are running in parallel with the R&D push. Pfizer is targeting an additional $2.7 billion in cuts between 2027 and 2029, bringing total targeted net savings to approximately $9.7 billion through 2029.
If the company hits both its revenue ambitions and cost targets, earnings are expected to pick up materially starting in 2029.
While investors wait, the dividend is doing some of the work. Pfizer pays a quarterly dividend of $0.43, translating to an annual yield of about 6.13%. With a payout ratio of roughly 0.58x against expected 2026 earnings, there is a reasonable buffer before that dividend comes under pressure.
Valuation Debate
Not everyone agrees the stock is cheap. Simply Wall St flags a GAAP P/E of 36.9x, above the pharmaceutical industry average of 16.8x and its own tailored fair multiple of 24.7x. That reading suggests the recent rally may have already priced in some optimism.
The two analyses are not necessarily contradictory. The non-GAAP multiple of 9.43x strips out items like acquisition-related charges, which are considerable given Pfizer’s recent deal activity.
On Wall Street, PFE carries a Moderate Buy consensus from eight Buy, 12 Hold, and one Sell rating over the past three months. The average price target sits at $28.46, implying about 1.37% upside from current levels.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
